Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Early Detection
100%
Novel Biomarkers
100%
Sensitive Detection
100%
Drug-induced Kidney Injury
100%
Cisplatin-induced Kidney Injury
100%
Cisplatin
87%
Cancer Control
87%
Percent Change
50%
Change from Baseline
50%
Adjudication
37%
Injury Rate
25%
Area under the Receiver Operating Characteristic (AUROC)
25%
Healthy Controls
12%
Serum Samples
12%
Urine Samples
12%
Median Time
12%
Diagnostic Accuracy
12%
Serum Biomarkers
12%
2-stage
12%
Patients with Cancer
12%
Time to Peak
12%
Receiver Operating Characteristic Curve
12%
Acute Kidney Injury
12%
Functional Biomarkers
12%
Exposure Area
12%
Cystatin C (Cys C)
12%
Urinary Neutrophil Gelatinase-associated Lipocalin (uNGAL)
12%
Clinical Drugs
12%
Urinary Biomarkers
12%
Injury Criteria
12%
Biomarker Profile
12%
Cisplatin Drug
12%
Injury Diagnosis
12%
Medicine and Dentistry
Biological Marker
100%
Kidney Injury
100%
Cisplatin
100%
Sensitive Detection
100%
Cancer Control
77%
Urinary System
44%
Observational Study
11%
Urine Sampling
11%
Diagnostic Accuracy
11%
Acute Kidney Injury
11%
Cystatin C
11%
Serum Group
11%
Neutrophil Gelatinase Associated Lipocalin
11%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Kidney Injury
100%
Cisplatin
100%
Malignant Neoplasm
88%
Observational Study
11%
Neutrophil Gelatinase Associated Lipocalin
11%
Acute Kidney Failure
11%
Cystatin C
11%